American Alpha Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$683K Buy
11,268
+374
+3% +$21.8K 0.36% 46
2025
Q4
$588K Buy
10,894
+1,375
+14% +$66.1K 0.35% 49
2025
Q3
$429K Buy
9,519
+41
+0.4% +$1.92K 0.3% 60
2025
Q2
$439K Buy
9,478
+1,023
+12% +$50.2K 0.34% 55
2025
Q1
$516K Sell
8,455
-666
-7% -$38.8K 0.43% 38
2024
Q4
$516K Sell
9,121
-599
-6% -$33.5K 0.45% 32
2024
Q3
$503K Buy
+9,720
New +$456K 0.46% 32

Other funds holding BMY

American Alpha Advisors's BMY Position: Q1 2026 in Review

American Alpha Advisors increased its Bristol-Myers Squibb (BMY) stake by 3.4% in Q1 2026, buying an estimated $21.8K and bringing the position to 11,268 shares worth $683K. The position accounts for 0.36% of the portfolio, ranked #46.

American Alpha Advisors first reported a position in BMY in Q3 2024 and has held it in 7 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • American Alpha Advisors held 11,268 shares of Bristol-Myers Squibb worth $683K as of Q1 2026.
  • American Alpha Advisors bought 374 Bristol-Myers Squibb shares in Q1 2026, an estimated $21.8K.
  • Bristol-Myers Squibb made up 0.36% of American Alpha Advisors's portfolio in Q1 2026, its #46 holding.
  • American Alpha Advisors first reported a position in Bristol-Myers Squibb in Q3 2024 and has held it in 7 quarters since.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on American Alpha Advisors's 13F filing for Q1 2026, filed 15 May 2026.